Posted by Michael Wonder on 09 Jan 2026
VectorY Therapeutics receives FDA fast track designation for VTx-002, a first in class vectorised antibody targeting underlying disease biology in ALS
8 January 2026 - VectorY Therapeutics announced today that the US FDA has granted fast track designation for VTx-002, a first-in-class vectorised antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis.
VTx-002 targets TDP-43 pathology, which drives up to 97% of amyotrophic lateral sclerosis cases.
